1 / 4

Time to Distant Metastases (ITT)

Time to Distant Metastases (ITT). Cumulative incidence of distant metastases (ITT). 0.10. Tamoxifen Exemestane. 0.08. 0.06. Probability. 0.04. 0.02. HR 0.81 (0.67-0.98; P <0.03). 0.00. 0.0. 0.5. 1.0. 1.5. 2.0. 2.5. Years since randomization. 4868. 26/4771. 69/4652. 53/4547.

byron-vaughan
Download Presentation

Time to Distant Metastases (ITT)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Time to Distant Metastases (ITT) Cumulative incidence of distant metastases (ITT) 0.10 Tamoxifen Exemestane 0.08 0.06 Probability 0.04 0.02 HR 0.81 (0.67-0.98; P<0.03) 0.00 0.0 0.5 1.0 1.5 2.0 2.5 Years since randomization 4868 26/4771 69/4652 53/4547 71/4406 110/4146 4898 29/4815 54/4733 47/4646 56/4510 112/4219 Adapted from Jones et al. SABCS 2008, abstract 15.

  2. DFS: On-Study Drug and Pre-Switch— Excluding 96 Never Treated Patients Cumulative probability 0.10 Tamoxifen Exemestane 0.08 0.06 Probability 0.04 0.02 HR 0.83 (95% CI 0.71-0.97, P=0.02) 0.00 0.0 0.5 1.0 1.5 2.0 2.5 Years since randomization Numbers at risk: Tamoxifen: 4817 28/4510 72/4207 63/3962 71/3664 87/2817 Exemestane: 4853 33/4552 64/4343 53/4210 47/4067 114/3779 Adapted from Jones et al. SABCS 2008, abstract 15.

  3. Recurrence According to Time *Events per woman entering time period. †Time since allocated treatment differed. Adapted from Jones et al. SABCS 2008, abstract 15.

  4. Breast Cancer Mortality, Death Without Recurrence, and Any Death Data *Time since allocated treatment differed. Adapted from Jones et al. SABCS 2008, abstract 15.

More Related